How is metastatic bladder cancer treated?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Inhibitors of programmed cell death 1 (PD-1) protein and its ligands PD-L1 and PD-L2, are first-line agents in patients with metastatic urothelial carcinoma who are not candidates for cisplatin chemotherapy, and second-line agents for those with disease progression despite cisplatin-based chemotherapy. Agents in this category include the following [1] :

  • Atezolizumab
  • Nivolumab
  • Durvalumab
  • Avelumab
  • Pembrolizumab

Erdafitinib, a fibroblast growth factor receptor inhibitor, is approved for locally advanced or metastatic urothelial carcinoma that has FGFR2 or FGFR3 genetic alterations and has progressed during or following at least 1 line of prior platinum-containing chemotherapy.

See Treatment and Medication for more detail. 

See Bladder Cancer Treatment Protocols for more information on this topic. Go to Oncology Decision Point for expert commentary on bladder cancer treatment decisions and related guidelines.

For patient education information, see Bladder Cancer.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!